Time To Take Profits On Gilead Sciences (Rating Downgrade) [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-year to $4.2 billion in Q4. On the other hand, sales of Gilead's oncology franchise leave much to be desired, despite its numerous attempts to compete with Merck, Pfizer, and AstraZeneca. I also believe Wall Street is overestimating the commercial prospects for anito-cel, a BCMA-directed CAR-T cell therapy, due to oversaturation in the multiple myeloma market. In this article, you will learn about additional reasons why, in my opinion, Gilead Sciences has lost its appeal as an attractive investment for long-term investors. We Are/DigitalVision via Getty Images Shares of Gilead Sciences, Inc. ( GILD ), my favorite in the HIV drugs market, have risen 23.3% since my previous article Gilead Sciences: From All-Time Highs To Higher Highs. And, of course, the primary reason behind this This article was written by Analyst's Disclosure: I/we have no sto
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Argus from $135.00 to $165.00. They now have a "buy" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $155.00 price target on the stock.MarketBeat
- Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Mizuho from $140.00 to $170.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $159.00 to $170.00. They now have a "buy" rating on the stock.MarketBeat
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- 2/17/26 - Form 144
- GILD's page on the SEC website